echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hengrui Medicine HR19042 capsule was approved for clinical use in the treatment of primary IgA nephropathy

    Hengrui Medicine HR19042 capsule was approved for clinical use in the treatment of primary IgA nephropathy

    • Last Update: 2021-04-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 7, Hengrui Medicine issued an announcement stating that it had recently received the approval of the National Medical Products Administration to issue the "Drug Clinical Trial Approval Notice" for HR19042 capsules, and clinical trials will be launched in the near future.


    On December 31, 2020, Hengrui Medicine submitted a clinical trial application for this product to the National Food and Drug Administration for the treatment of primary IgA nephropathy.


    Up to now, HR19042 related research and development projects have invested about 5.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.